3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
9
Breast Neoplasms
6
Neoplasms
4
Colorectal Neoplasms
3
Multiple Myeloma
2
Insulin Resistance
2
Cardiotoxicity
2
Weight Loss
1
Warts
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Peripheral Nervous System Diseases
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Lymphoma
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Fatigue
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus
1
Cognitive Dysfunction
1
Carcinoma, Hepatocellular
1
Cachexia
1
Brenner Tumor
1
Bone Metastases
1
Body Weight
1
Interventions
pembrolizumab
26
atezolizumab
14
Nivolumab
13
Gemcitabine
13
Cisplatin
10
Docetaxel
8
Carboplatin
8
avelumab
7
Mitomycin
7
epacadostat
4
cabozantinib
4
Ipilimumab
4
pemigatinib
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Bevacizumab
3
vofatamab
2
rucaparib
2
lenvatinib
2
enfortumab vedotin
2
durvalumab
2
cabazitaxel
2
bempegaldesleukin
2
Standard of Care
2
Rogaratinib
2
Ramucirumab
2
Radiation
2
Platinum
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Transitional Cell
×
Exercise
×
Clear all
No trials found.